Cole Brennan: Hey — glad the weather finally broke, by the way. I was starting to think we'd just live in that heat forever.
Malcolm Reeves: It did feel biblical for a stretch. Now — I've been sitting on something for this episode. I want to try something. I'm going to give you a number and I want your gut reaction before any context.
Malcolm Reeves: 797 per 100,000. Then 36 per 100,000. Same country, same metric — infectious disease mortality in the United States. 1900 versus 1980. CDC's own historical record.
Cole Brennan: That's — wait, 797 to 36? In eighty years? That's not a medical advance, that's like... a category of death basically disappearing.
Malcolm Reeves: And in the same period, deaths from cancer and heart disease climbed steadily. So we didn't just win one war — we cleared the field for a different one. And we walked onto that new field with the exact same weapons.
Cole Brennan: The weapons being — germ theory, essentially. Pasteur and Koch's whole framework. Find the pathogen, target it, done.
Malcolm Reeves: Koch identified Mycobacterium tuberculosis. 1882. And what that did — beyond just naming the bug — is it gave medicine a logic. One cause, one intervention, one endpoint. That logic is still running the show. And now we have obesity, type 2 diabetes, cardiovascular disease. Multicausal, no discrete pathogen, no clean endpoint. And medicine keeps reaching for the same logic.
Cole Brennan: For real though — and here's the part I keep snagging on. We talk about infectious disease like it's handled. But the WHO put 1.25 million TB deaths in 2023. So the tools work, just not everywhere. Which means even the 'solved' problem is only solved for people with access to the solution.
Malcolm Reeves: And that asymmetry, access determining outcomes, is about to repeat itself with chronic disease. The question sitting at the center of all of this is: if medicine's entire intellectual architecture was built to kill pathogens, what does it do when there's no pathogen to kill?
Cole Brennan: Yeah, and I don't think it has a clean answer yet. Which is kind of the unsettling part.
Malcolm Reeves: But that's exactly where the story gets slippery. Because we keep saying 'medicine solved infectious disease' — and the CDC data shows the collapse, yes — but the data doesn't isolate what did the work. Antibiotics, sanitation, clean water, improved nutrition. All of it layered. And we handed the credit to the pharmaceutical side of it.
Cole Brennan: Wait — so we don't actually know how much penicillin did versus, like, sewers?
Malcolm Reeves: The CDC's own historical reviews document the mortality decline across the century. But sources genuinely disagree on the weighting. Antibiotics mattered. And nutrition and clean water mattered first. Those two facts coexist.
Cole Brennan: Actually, no, here's how I keep picturing it. You've got a leaky roof in a rainstorm. Someone grabs a bucket and catches the water. The flooding stops. But someone else had already patched most of the holes before the bucket even appeared. Medicine shows up with the bucket and says 'we fixed it.' And maybe they did — but we genuinely don't know how many holes were already patched.
Malcolm Reeves: That's it. That's the attribution error.
Cole Brennan: And the wild thing is — the trap it sets. Because if you believe the bucket won, then every new problem, you reach for a bucket. Which is exactly what's happening with obesity and type 2 diabetes. Multicausal, no pathogen, no clean endpoint — and we're still looking for the single targeted intervention.
Malcolm Reeves: Now, that's the epidemiological transition made concrete. Infectious disease recedes, chronic non-communicable disease becomes the leading killer, and medicine arrives at that new war perfectly equipped for the old one.
Cole Brennan: Optimized for the wrong enemy.
Malcolm Reeves: And the acute disease paradigm made the optimization feel like wisdom — one pathogen, one intervention, finite treatment course, measurable endpoint. Cure or death. You know when you've won. Chronic metabolic disease doesn't give you that moment.
Cole Brennan: There's no — I mean, what even is the endpoint for type 2 diabetes? It's not 'cured.' It's managed. Indefinitely. Which is a completely different thing medicine doesn't — I don't think it was built for that.
Malcolm Reeves: It was not. The institution, the incentives, the very logic running since Koch named Mycobacterium tuberculosis in 1882 — all of it assumes there is a discrete enemy to eliminate. And that assumption is the problem, not the competence of the people working inside it.
Cole Brennan: The question is — if sanitation and clean water did as much heavy lifting as the drugs did, maybe even more, then why is the entire chronic disease conversation still centered on finding a better drug? Why aren't we asking what the twenty-first-century equivalent of a sewer system is?
Malcolm Reeves: That sewer question is exactly the right one — and it lands hardest when you put a specific person inside it. A woman named Diane, fifty-four, walks out of her endocrinologist's office with a type 2 diabetes diagnosis. She's holding a metformin prescription and a pamphlet. The prescription has a start date. There is no end date. No one tells her when she's done, because there is no done.
Cole Brennan: No clearance moment.
Malcolm Reeves: None. Koch's logic — one pathogen, one intervention, finite course — gives you a moment where you've won. Diane doesn't get that moment. And the clinical system treating her was not built to handle that absence. It was built for the prescription encounter. Not the six months of follow-up she actually needs.
Cole Brennan: And the reimbursement structure — I mean, that's not just habit, right? That's baked in structurally. The fifteen-minute appointment gets paid. The ongoing coaching doesn't.
Malcolm Reeves: Structurally, yes. Which is why what the American College of Lifestyle Medicine is documenting is so striking — practitioners are achieving medication de-escalation, actual type 2 diabetes remission, through lifestyle modification alone. Not managed. Reversed. But the system has no reimbursement pathway built for the intervention that produces that outcome.
Cole Brennan: Wait — remission? That's a different word than management.
Malcolm Reeves: It is. And the ACLM is using it deliberately. But here's the gap — the clinical infrastructure can't deliver it at scale because it was designed around the acute-infectious model. Deliver the drug, close the chart.
Cole Brennan: And what makes chronic metabolic disease actually different — not just harder, but differently structured — is the multicausality piece. Diane's diabetes isn't one thing. It's genetics, it's her neighborhood's food environment, it's sleep, it's decades of behavior. There's no pathogen to name. No Mycobacterium tuberculosis equivalent. So the target doesn't exist the same way.
Malcolm Reeves: And yet we keep designing interventions as if there is one. Which is the paradigm mismatch made concrete — it's not that the doctors are wrong, it's that the institutional design keeps asking for a target when the disease is the system.
Cole Brennan: There's one more layer that actually blurs all of this further — metabolic dysfunction, like obesity or insulin resistance, it increases susceptibility to infectious disease. And chronic infection can worsen metabolic outcomes. So the clean boundary between the two paradigms was always partially a fiction.
Malcolm Reeves: Is that right — the causation runs both directions?
Cole Brennan: Both directions. Which means we didn't just inherit the wrong tools — we inherited a map with a border on it that the biology doesn't respect.
Malcolm Reeves: And that border is going to get tested hard when we get to GLP-1 receptor agonists — because semaglutide is the most serious pharmaceutical challenge to everything we just said, and it still doesn't close the structural gap in the way you'd want it to.
Cole Brennan: Right — but the challenge to everything we just said is that semaglutide isn't doing one thing. It's hitting pancreatic insulin secretion, gastrointestinal motility, and central appetite regulation simultaneously. That's not a bucket. That's something genuinely different.
Malcolm Reeves: And the WHO issuing a formal guideline calling on nations to ensure access — that's not a small signal.
Cole Brennan: No, it's not. That's institutional recognition. Which made me think — wait, is this the antibiotic moment for chronic disease? Like, finally a drug with a pharmacological profile that doesn't have a clear prior precedent?
Malcolm Reeves: But there's a phrase in there that breaks the analogy. Lifelong use. Antibiotics have a course. You stop taking them. Semaglutide — you stop taking it, the weight returns. That's not a treatment in the Koch sense. That's a subscription.
Cole Brennan: That's — yeah, that's the thing that actually unsettles me about the comparison.
Malcolm Reeves: Now, the cardiovascular protection piece is real — GLP-1 agonists showing benefits across diabetes and obesity simultaneously, that's a pharmacological profile without a clear precedent. I'll grant that. But 'without precedent' and 'solves the structural problem' are two different claims.
Cole Brennan: Okay but — actually, no, I want to push on the behavior-change assumption for a second. Because the thing about semaglutide suppressing hunger signals neurologically — I mean, that's not the patient deciding to eat less. The drug is rewiring the appetite signal. So maybe the behavior-change burden actually is different here?
Malcolm Reeves: Is that right — the ACLM position is that lifestyle medicine can get medication de-escalation and actual remission in type 2 diabetes. Without the drug. But — and this is the part that holds me — it only reaches the patients the system is already set up to serve.
Cole Brennan: So GLP-1s and lifestyle medicine have the same access problem, just differently priced.
Malcolm Reeves: Differently priced, yes. Thousands a month indefinitely versus — well, a healthcare system that actually follows up. Neither is cheap at scale.
Cole Brennan: And then there's the question the field is now openly sitting with — what does success even mean? Because the WHO guideline isn't just listing weight loss as the endpoint anymore. Health-related quality of life. Body image. Weight bias internalization. That's — I mean, those aren't the same as 'pathogen cleared.'
Malcolm Reeves: The field is debating its own definition of cure. That's not a solved paradigm. That's a paradigm in motion.
Cole Brennan: Which lands the hardest question for me — if we can't define the endpoint, how does a clinician know when treatment is working? And who actually decides when to stop?
Malcolm Reeves: And that question — who decides, and by what measure — that's not a pharmacology problem. That's the design problem Koch's logic was never built to answer.
Cole Brennan: And that's — I mean, that's not a pharmacology problem and it's not a willpower problem either. It's that the 797-to-36 collapse made everyone so confident in the model that the model became invisible. Like, you don't question the logic that just pulled off the most dramatic public health drop in recorded history.
Malcolm Reeves: Now that number — 797 per 100,000, then 36 — I've been carrying it since we started this conversation and it lands differently now. At the top of the hour it felt like triumph. And it still is. But it's also... a trap that got set the moment we decided to call it a pharmaceutical victory.
Cole Brennan: The sewers don't get a press release.
Malcolm Reeves: They do not. And so the lesson medicine wrote down was: find the pathogen, build the drug, win the war. And now GLP-1 agonists arrive — semaglutide hitting pancreatic, gastrointestinal, neurological systems simultaneously, the WHO calling on nations to ensure access — and it's the most serious pharmaceutical candidate the chronic disease era has produced. I don't want to understate that. But lifelong use at thousands a month is not the same sentence as 'penicillin, ten days, done.' That's the part that won't resolve.
Cole Brennan: And if the next decade prices the best tools at a premium and leaves the food environment, the built environment — all the stuff that's actually driving the disease — unchanged... I mean, are we solving chronic disease? Or are we just managing it for the people who can afford the subscription?
Malcolm Reeves: That's the question I don't have an answer to. And I think it's the right question to not have an answer to.
Cole Brennan: Yeah. We started with a number that felt like medicine winning. And we ended with... the same number, kind of. Just asking what it actually cost, and who it didn't reach.
Malcolm Reeves: Good place to stop. Thank you for this one.
